Managed Account Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Managed Account Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$219M	Sell	1,777,380 -108,705	-6%	-$13.7M	0.18%	148
2015 Q1	$223M	Buy	1,886,085 +477,522	+34%	+$57.2M	0.2%	140
2014 Q4	$167M	Buy	1,408,563 +291,005	+26%	+$32.8M	0.17%	155
2014 Q3	$126M	Buy	1,117,558 +185,017	+20%	+$17.6M	0.14%	178
2014 Q2	$88.3M	Sell	932,541 -239,756	-20%	-$16.8M	0.11%	226
2014 Q1	$82.9M	Buy	1,172,297 +166,562	+17%	+$13.2M	0.11%	226
2013 Q4	$74.7M	Sell	1,005,735 -307,412	-23%	-$21.4M	0.1%	238
2013 Q3	$99.6M	Sell	1,313,147 -551,057	-30%	-$43.9M	0.15%	172
2013 Q2	$149M	Buy	+1,864,204	New	+$137M	0.23%	104

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Managed Account Advisors's VRTX Position: Q2 2015 in Review

Managed Account Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 5.8% in Q2 2015, selling an estimated $13.7M and leaving 1,777,380 shares worth $219M. The position accounts for 0.18% of the portfolio, ranked #148.

Managed Account Advisors first reported a position in VRTX in Q2 2013 and has held it in 9 quarters since. The position peaked at $223M in Q1 2015. 501 funds tracked by Wall St. Rank hold VRTX as of Q2 2015.

Managed Account Advisors held 1,777,380 shares of Vertex Pharmaceuticals worth $219M as of Q2 2015.
Managed Account Advisors sold 108,705 Vertex Pharmaceuticals shares in Q2 2015, an estimated $13.7M.
Vertex Pharmaceuticals made up 0.18% of Managed Account Advisors's portfolio in Q2 2015, its #148 holding.
Managed Account Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Vertex Pharmaceuticals position peaked at $223M in Q1 2015.
501 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.